Presenter(s): Nathan Geffen

Venue: CSSR Seminar Room 4.29, Level 4 Leslie Social Science Building, Upper Campus

Abstract / Description: 

Prevalence of drug-resistant TB is increasing. Treatment regimens have to be taken, typically, for two years and have poor outcomes. Most second-line TB medicines have poor evidence to support their use and are associated with terrible side effects. In 2010, no new class of TB drug had been approved in several decades. Based on the historical examples of campaigns for HIV medicines in the 1980s and 1990s in Europe and the US, the Global TB Community Advisory Board, TAC and other organisations began campaigning for pre-regulatory approval access to an experimental drug called bedaquiline. I will discuss the complex scientific and ethical challenges brought to the fore by this campaign